AgingMETRIX

EpiDisease is offering AgingMETRIX, a commercially available and clinically validated epigenetic biological age test based on ELOVL2 gene methylation analysis using pyrosequencing technology.

Delivered via a simple, non-invasive saliva self-sampling kit with results in 21 days, it achieves an R² of 0.83 — matching the industry gold standard Horvath clock.

The test is currently marketed direct-to-consumer in Spain and is suited for wellness, longevity, preventive health, and clinical research applications.

We are looking for distribution partners, licensing agreements, integration into wellness or preventive health platforms, and co-development opportunities with longevity-focused companies or insurers seeking evidence-based biological age biomarkers.

https://epidisease.com/en/2025/04/08/a-sex-specific-minimalcpg-based-model-forbiological-agingusing-elovl2-methylation-analysis/

https://epidisease.com/en/2024/11/05/physical-activity-epigenetic-aging-in-breast-cancer-treatment/